Labcorp Options Hedging Spikes as Q3 Results Land

Labcorp Holdings reported Q3 results on October 28 with options traders running their most defensive positioning in months, even as short sellers quietly retreated from the stock.

The clearest shift this week is in the options market. The put/call ratio climbed to 1.27 on October 27, more than three standard deviations above its 20-day mean of 1.18. That is the most elevated defensive reading since the ratio spiked to 3.30 at its 52-week high, and a sharp move from the 1.20 level flagged in last week's earnings preview note. The jump happened in the session immediately following the Q3 print, suggesting investors reacted by adding downside protection rather than unwinding hedges. Closest peer Quest Diagnostics gained 2.3% on the week, broadly in step with Labcorp's 2.5% advance, so the defensive options tilt looks company-specific rather than a sector-wide rotation.

Short interest tells a more relaxed story. Shorts trimmed positions by roughly 5.6% over the past week, bringing short interest to 2.9% of the free float, a level low enough to carry no meaningful squeeze risk. Borrow costs confirm the lack of pressure: cost to borrow is running at 0.41%, and availability is extraordinarily loose at 4,531%, meaning there are roughly 45 shares available to lend for every one currently borrowed. That availability reading has loosened materially from 1,758% in mid-September, when borrow was tighter. Nothing in the lending market suggests bearish conviction. Short interest is up about 28% over the past month in share terms, but from a low base, and the week's direction has been the opposite: a steady reduction each day from Monday through Tuesday.

The Street has been consistently constructive on Labcorp all year. After Q2 results in late July, JP Morgan raised its target to $360 and Morgan Stanley moved to $338, both reiterating positive ratings. In September, Truist lifted to $365 and UBS moved to $380, both keeping Buy recommendations. Barclays sits more cautiously at an Equal-Weight with a $330 target, essentially in line with the current price of $331.17. The bull case rests on the 7.5% revenue growth in the Central Lab segment, an $8.71 billion backlog up 10% year on year, and an 8.9% gain in the Diagnostic segment. Bears point to reimbursement policy risk under PAMA and total requisition volume growth of 4.9%, which fell short of the 5.2% the market had pencilled in. Valuation sits at roughly 17 times earnings, up about 6% over the past month as the stock has re-rated with the broader price move.

Retail attention has ticked up too. Wikipedia page views and ORTEX stock page traffic for Labcorp are running more than two standard deviations above their own 90-day averages, a reading dated October 23. That kind of elevated retail attention tends to coincide with earnings events rather than being a sustained signal, but it reinforces the picture of a stock that drew unusual scrutiny into the print.

Institutionally, the register is stable. BlackRock holds 8.1% and Vanguard entities account for roughly 12% combined, with all three passive filings reflecting 13G status and no activist presence. Boston Partners added 682,894 shares through August, and FMR built a 620,714-share position over the same period, the two most notable active-manager moves in the recent cycle. On the insider side, the 90-day net across all transaction types is negative at around $3.5 million, though the material sales from CEO Adam Schechter and director Kerrii Anderson in August were both executed under pre-arranged 10b5-1 plans, reducing the directional signal they would otherwise carry.

With Q3 results now in, the focus shifts to management commentary on PAMA reimbursement timing and whether the Central Lab backlog conversion rate is tracking the 1.11x book-to-bill ratio cited in the bull case.